Scientists are voicing concerns over the design of a French drug trial that left one participant dead and several others with severe health problems — and they are calling for more information to be released. The researchers, including those in the UK’s Royal Statistical Society (RSS), have examined a document that describes how the trial was conducted, and say that major pieces of information are still missing.